# US 2012/0252689 A1 · Gene expression signature for wnt/b-catenin signaling pathway and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252689 A1
- Document ID: US20120252689A1
- Status: Published application
- Kind: A1
- Application number: 13/437,344
- Filed: 2012-04-02
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Inventors: Zhong Wu; John DiCarlo; Yexun Wang
- Web page: https://patentgrep.com/patent/US20120252689A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a novel set of 16 biomarkers, microarrays that provide for the detection thereof, an expression signature comprising 16 genes or a subset thereof, and the use thereof in determining the regulation status of Wnt/β-catenin signaling pathway. The regulation status of Wnt/β-catenin signaling pathway may be assayed based on the level of expression of one or more of these genes. The expression of these biomarkers may be used to evaluate Wnt/β-catenin pathway deregulation status; classify a cell sample as having a deregulated or regulated Wnt/β-catenin signaling pathway; determine whether an agent modulates the Wnt/β-catenin signaling pathway; predict response of a subject to an agent that modulates the Wnt/β-catenin signaling pathway; assign treatment to a subject; or evaluate the pharmacodynamic effects of therapies designed to regulate Wnt/β-catenin pathway signaling.

## Claims

### Claim 1

A microarray composition for effecting amplification analysis of a sample to detect the regulation status of Wnt/β-catenin signaling pathway in a cell sample or subject, wherein the composition comprises sequences that amplify and provide for the detection of at least 5 of the genes selected from the group consisting of CALM1, CCND1, CCND2, CHSY1, CXADR, CYP4V2, FAM44B, HSPA12A, LEF1, MTP18, MYC, NAV2, SKP2, PRMT6, MTSS1 and MT1A or an ortholog or variant thereof.

### Claim 2 (depends on 1)

The microarray composition of claim 1 wherein the amplified genes are at least 90% identical or specifically hybridize to genes with Accession numbers selected from the group consisting of NM—006888.4, NM—053056.2, NM—001759.3, NM—014918.3, NM—001338.4, NM—207352.3, NM—138369.2, NM—025015.2, NM—016269.4, NM—016498.4, NM—002467.4, NM—145117.4, NM—005983.3, NM—018137.2, NM—014751.4, and NM—005946.2.

### Claim 3 (depends on 1)

The microarray composition of claim 1 for effecting amplification analysis of a sample to detect the regulation status of Wnt/β-catenin signaling pathway in a cell sample or subject, wherein the composition comprises sequences that amplify and provide for the detection of at least 10 of the genes selected from the group consisting of CALM1, CCND1, CCND2, CHSY1, CXADR, CYP4V2, FAM44B, HSPA12A, LEF1, MTP18, MYC, NAV2, SKP2, PRMT6, MTSS1 and MT1A.

### Claim 4 (depends on 1)

The microarray composition of claim 1 which further comprises sequences corresponding to from 1-10 housekeeping genes.

### Claim 5 (depends on 1)

The microarray composition of claim 1 for effecting amplification analysis of a sample to detect the regulation status of Wnt/β-catenin signaling pathway in a cell sample or subject, wherein the composition comprises sequences that amplify and provide for the detection of at least 10-15 of the genes selected from the group consisting of CALM1, CCND1, CCND2, CHSY1, CXADR, CYP4V2, FAM44B, HSPA12A, LEF1, MTP18, MYC, NAV2, SKP2, PRMT6, MTSS1 and MT1A.

### Claim 6 (depends on 1)

The microarray composition of claim 1 for effecting amplification analysis of a sample to detect the regulation status of Wnt/β-catenin signaling pathway in a cell sample or subject, wherein the composition comprises sequences that amplify and provide for the detection of all 16 of the genes selected from the group consisting of CALM1, CCND1, CCND2, CHSY1, CXADR, CYP4V2, FAM44B, HSPA12A, LEF1, MTP18, MYC, NAV2, SKP2, PRMT6, MTSS1 and MT1A.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The microarray composition of claim 1 which is for effecting amplification by a method comprising: polymerase chain reaction (PCR), strand displacement amplification (SDA), loop-mediated isothermal amplification (LAMP), rolling circle amplification (RCA), transcription-mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence based amplification (NASBA), or reverse transcription polymerase chain reaction (RT-PCR), or is for effecting real-time PCR amplification, or is for effecting real-time PCR amplification with detection by a SYBR Green method, or is for effecting detection by an MNAzyme method.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A method of using an array according to claim 1 to determine the regulation status of Wnt/β-catenin signaling pathway in a cell sample or subject.

### Claim 12 (depends on 11)

The method of claim 11 wherein after running the amplification array, the data is analyzed using a web based analysis tool.

### Claim 13 (depends on 12)

The method of claim 12 wherein this tool provides a number that is used to determine the regulation status of Wnt/β-catenin signaling pathway in the target as compared to a control sample.

### Claim 14

A method of determining the regulation status of Wnt/β-catenin signaling pathway in a cell sample or subject comprising detecting and comparing the expression of one or more of the genes selected from the group consisting of CALM1, CCND1, CCND2, CHSY1, CXADR, CYP4V2, FAM44B, HSPA12A, LEF1, MTP18, MYC, NAV2, SKP2, PRMT6, MTSS1 and MT1A. to the expression of the same genes by a control cell sample and based on this comparison determining the regulation status of the Wnt/β-catenin signaling pathway in a cell sample or subject.

### Claim 15 (depends on 14)

The method of claim 14 wherein gene expression is assayed by real time amplification, or wherein the detection method comprises SYBR Green based real-time PCR.

### Claim 16

(canceled)

### Claim 17 (depends on 14)

The method of claim 14 wherein the gene expression data is analyzed by a support vector machine method.

### Claim 18 (depends on 17)

The method of claim 17 wherein the expression value of all 16 genes plus house keeping genes is measured on control and treatment sample and the ΔΔCt is calculated and the ΔΔCt value of those 16 genes is compared to ΔΔCt value of these 16 genes in a data pool that contains negatively regulated and positively regulated samples in terms of pathway activity.

### Claim 19 (depends on 14)

The method of claim 14 wherein a cell sample is obtained from a patient that is potentially to be treated with a compound that modulates Wnt/β-catenin signaling and the method is used to assess the treatment protocol.

### Claim 20 (depends on 14)

The method of claim 14 wherein a cell sample is obtained from a patient that has been treated with a compound that modulates Wnt/β-catenin signaling and the method is used to assess the efficacy of the treatment protocol.

### Claim 21 (depends on 14)

The method of claim 14 which is used to evaluate Wnt/β-catenin pathway deregulation status in a sample, or which is used to classify a cell sample as having a deregulated or regulated Wnt/b-catenin signaling pathway.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 14)

The method of claim 14 which is used to predict the response of a subject to an agent that modulates the Wnt/β-catenin signaling pathway, is used to determine whether an agent modulates the Wnt/b-catenin signaling pathway in sample, or is used to evaluate the pharmacodynamic effects of therapies designed to regulate Wnt/b-catenin pathway signaling.

### Claim 25 (depends on 24)

The method of claim 24 which is used to assign treatment to a subject.

### Claim 26

(canceled)

### Claim 27 (depends on 14)

The method of claim 14 which is used to identify a cancer characterized by Wnt/β-catenin pathway dysregulation, wherein said cancer optionally is selected from colorectal carcinomas, melanomas, breast cancer and hepatocellular carcinomas.

### Claim 28

(canceled)
